Date: 2015-08-04
Type of information: Capital increase
Company: Biophytis (France)
Investors: undisclosed US investor
Amount: €6 million
Funding type: capital increase
Planned used: These additional funds will be used to support Biophytis’ development. Biophytis is specialized in aging diseases. The company develops therapeutic solutions on pathologies to restore the muscular and visual functions. R&D efforts are focused in the fight against the age-related macular degeneration (AMD) and the age-related muscular dystrophy (Sarcopenia). On these two highly invalidating diseases, the company has proprietary candidates entering in phase 2b.
Others: * On August 4, 2015, Biophytis, a french company specialized in the development of drug candidates to treat the aging diseases, today has raised €6 million via an €6 million international private placement. Following its IPO on the Alternext market in Paris in July 2015, the company raised additional funds with a US investor to support the Company’s development. The Company has thus issued 666,700 new shares at a nominal value of €0.20 each for a total of €6,000,300.
This operation was carried out following the decisions adopted by the Board meetings of August 4, 2015 in accordance with the
delegation of powers granted by the Shareholders’ Meeting of May 27, 2015 and at a negotiated price representing a 14%
discount on the average closing price of the Company’s share over the last 10 trading days prior to the launch of the operation.
The capital increase was carried out via the issuance of ordinary shares without preferential subscription rights through a private
placement amongst qualified investors in accordance with article L. 225-136 of the French Commercial Code and article L. 411-
2 II of the Monetary and Financial Code. The new shares carry dividend rights and will be admitted to trading on the Alternext regulated market in Paris under ISIN FR0012816825 – ALBPS.
Within the framework of this capital increase, BIOPHYTIS signed a lock-up commitment regarding the Company’s shares of 90
days from August 5, 2015, subject to certain usual exceptions. Biophytis’ share capital now consists of 6,108,835 shares. For information, a shareholder holding 1.00% of the Company’s share capital prior to the operation would now hold 0.89% of its share capital.
Therapeutic area: Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases
